Home › Lung Diseases › Nevada › Las Vegas
Lung Diseases clinical trials in Las Vegas, NV
3 studies for Lung Diseases are looking for participants at sites in and around Las Vegas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Comprehensive Cancer Centers of Nevada, Las Vegas
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
RecruitingPhase 2
- Comprehensive Cancer Centers of Nevada - Central Valley - Twain, Las Vegas
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
RecruitingPhase 1Healthy volunteers welcome
- PPD - Las Vegas Research Unit, Las Vegas
About Lung Diseases
Lung diseases are disorders or infections that affect the lungs and cause breathing problems. Some can lead to respiratory failure. Find out more about prevention, living with lung diseases, and treatment.
More about Lung Diseases on MedlinePlus
Lung Diseases trials in other cities
- Houston, TX15 studies
- Boston, MA14 studies
- Durham, NC13 studies
- New York City, NY12 studies
- Pittsburgh, PA11 studies
- Los Angeles, CA10 studies
- Columbus, OH10 studies
- Dallas, TX10 studies
- Nashville, TN10 studies
- Washington, DC10 studies
- Miami, FL10 studies
- Ann Arbor, MI10 studies
Other studies in Las Vegas
- Obesity27 studies
- Overweight23 studies
- Type 2 Diabetes18 studies
- Non-Small Cell Lung Cancer13 studies
- Major Depressive Disorder13 studies
- Breast Cancer10 studies
- Alzheimer's Disease8 studies
- Prostate Cancer8 studies
- Acute Myeloid Leukemia8 studies
- Cancer (all types)8 studies
- Steatotic Liver Disease7 studies
- Endometrial Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.